Ocugen Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
95
- Stock Symbol
-
OCGN
- Investments
-
1
- Share Price
-
$0.74
- (As of Thursday Closing)
Ocugen General Information
Description
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Contact Information
Website
www.ocugen.comCorporate Office
- 11 Great Valley Parkway
- Malvern, PA 19355
- United States
Corporate Office
- 11 Great Valley Parkway
- Malvern, PA 19355
- United States
Ocugen Stock Performance
As of 24-Apr-2025, Ocugen’s stock price is $0.74. Its current market cap is $215M with 292M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.74 | $0.72 | $0.52 - $2.06 | $215M | 292M | 3.81M | -$0.20 |
Ocugen Financials Summary
As of 31-Dec-2024, Ocugen has a trailing 12-month revenue of $4.05M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 202,600 | 202,600 | 100,488 | 189,424 |
| Revenue | 4,055 | 4,055 | 6,036 | 2,488 |
| EBITDA | (52,086) | (52,086) | (62,374) | (86,324) |
| Net Income | (54,054) | (54,054) | (63,078) | (86,804) |
| Total Assets | 82,442 | 82,442 | 64,547 | 108,632 |
| Total Debt | 32,503 | 32,503 | 6,941 | 6,374 |
Ocugen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ocugen Comparisons
Industry
Financing
Details
Ocugen Competitors (26)
One of Ocugen’s 26 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Cyanvac | Venture Capital-Backed | Athens, GA | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Oxford BioMedica | Corporation | Oxford, United Kingdom |
Ocugen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ocugen Patents
Ocugen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250049912-A1 | Multicistronic vaccine and methods for producing and using the same | Pending | 23-Feb-2023 | ||
| US-20240148830-A1 | Treatment of neurological disorder using nhr | Pending | 07-Nov-2022 | ||
| AU-2023375892-A1 | Treatment of neurological disorder using nhr | Pending | 07-Nov-2022 | ||
| US-20210123077-A1 | Adeno-associated virus vector mediated gene therapy for ophthalmic diseases | Pending | 27-Apr-2019 | ||
| EP-3752524-A1 | Adeno-associated virus vector mediated gene therapy for ophthalmic diseases | Pending | 27-Apr-2019 | C12N15/86 |
Ocugen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ocugen Acquisitions (1)
Ocugen’s most recent deal was a Merger/Acquisition with Histogenics. The deal was made on 30-Sep-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Histogenics | 30-Sep-2019 | Merger/Acquisition | Therapeutic Devices |
Ocugen ESG
Risk Overview
Risk Rating
Updated April, 25, 2023
26.24 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,842
Rank
Percentile
Pharmaceuticals
Industry
of 898
Rank
Percentile
Biotechnology
Subindustry
of 402
Rank
Percentile
Ocugen FAQs
-
When was Ocugen founded?
Ocugen was founded in 2013.
-
Where is Ocugen headquartered?
Ocugen is headquartered in Malvern, PA.
-
What is the size of Ocugen?
Ocugen has 95 total employees.
-
What industry is Ocugen in?
Ocugen’s primary industry is Biotechnology.
-
Is Ocugen a private or public company?
Ocugen is a Public company.
-
What is Ocugen’s stock symbol?
The ticker symbol for Ocugen is OCGN.
-
What is the current stock price of Ocugen?
As of 24-Apr-2025 the stock price of Ocugen is $0.74.
-
What is the current market cap of Ocugen?
The current market capitalization of Ocugen is $215M.
-
What is Ocugen’s current revenue?
The trailing twelve month revenue for Ocugen is $4.05M.
-
Who are Ocugen’s competitors?
Regenxbio, Sangamo Therapeutics, Cyanvac, ONL Therapeutics, and Oxford BioMedica are some of the 26 competitors of Ocugen.
-
What is Ocugen’s annual earnings per share (EPS)?
Ocugen’s EPS for 12 months was -$0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
